Follow
Jianan Hui
Jianan Hui
Servier Pharmaceuticals
Verified email at ucr.edu
Title
Cited by
Cited by
Year
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
P Montesinos, C Recher, S Vives, E Zarzycka, J Wang, G Bertani, ...
New England Journal of Medicine 386 (16), 1519-1531, 2022
2322022
AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib+ azacitidine versus placebo+ azacitidine in patients with newly diagnosed acute myeloid leukemia with an …
P Montesinos, C Recher, S Vives, E Zarzycka, J Wang, G Bertani, ...
Blood 138, 697, 2021
152021
Correct and logical causal inference for binary and time‐to‐event outcomes in randomized controlled trials
Y Liu, B Wang, M Yang, J Hui, H Xu, S Kil, JC Hsu
Biometrical Journal 64 (2), 198-224, 2022
142022
A machine learning approach to galaxy–LSS classification–I. Imprints on halo merger trees
J Hui, M Aragon, X Cui, JM Flegal
Monthly Notices of the Royal Astronomical Society 475 (4), 4494-4503, 2018
92018
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers
T Litzenburger, J Steffgen, E Benediktus, F Müller, A Schultz, E Klein, ...
British Journal of Clinical Pharmacology 87 (4), 1824-1838, 2021
52021
Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib+ azacitidine compared to placebo+ azacitidine.
S De Botton, P Montesinos, S Vives Polo, E Zarzycka, J Wang, M Riva, ...
Journal of Clinical Oncology 41 (16_suppl), 7012-7012, 2023
22023
Molecular characterization of clinical response and relapse in patients with IDH1m ND-AML treated with Ivo+ AZA in the AGILE study
H Döhner, DM Marchione, S Choe, P Montesinos, C Recher, S Vives, ...
Blood 140 (Supplement 1), 539-542, 2022
22022
Empirical profile Bayesian estimation for extrapolation of historical adult data to pediatric drug development
Y Wu, J Hui, Q Deng
Pharmaceutical Statistics 19 (6), 787-802, 2020
22020
AML-446 Time to Resolution of Myelosuppression and Associated Hospitalization in Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML) Treated With Ivosidenib (IVO)+ …
AT Fathi, BD Smith, A Angiolillo, G Binder, J Hui, R Guo, C Cerchione
Clinical Lymphoma Myeloma and Leukemia 23, S302, 2023
12023
AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib+ Azacitidine Versus Placebo+ Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia …
H Dohner, P Montesinos, SV Polo, E Zarzycka, J Wang, G Bertani, ...
Clinical Lymphoma Myeloma and Leukemia 22, S234, 2022
12022
Optimal biomarker cutoff identification and validation
J Hui, W Guo
Statistics in Biosciences 14 (2), 352-362, 2022
12022
Molecular Measurable Residual Disease in Patients with Newly Diagnosed m IDH1 Acute Myeloid Leukemia Treated with Ivosidenib+ Azacitidine
CD DiNardo, D Marchione, M Heuser, J Hui, D Gianolio, S Daigle, S Choe, ...
Blood 142, 4305, 2023
2023
Single-arm phase II three-outcome designs with handling of over-running/under-running
W Guo, J Hui, B Zhong
Statistical Theory and Related Fields 7 (4), 276-286, 2023
2023
AML-469 Ivosidenib+ Azacitidine vs Placebo+ Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study
S de Botton, P Montesinos, SV Polo, E Zarzycka, J Wang, M Riva, ...
Clinical Lymphoma Myeloma and Leukemia 23, S304, 2023
2023
POSTER: AML-446 Time to Resolution of Myelosuppression and Associated Hospitalization in Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML) Treated With Ivosidenib (IVO …
AT Fathi, BD Smith, A Angiolillo, G Binder, J Hui, R Guo, C Cerchione
Clinical Lymphoma Myeloma and Leukemia 23, S163, 2023
2023
POSTER: AML-469 Ivosidenib+ Azacitidine vs Placebo+ Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the …
S de Botton, P Montesinos, SV Polo, E Zarzycka, J Wang, M Riva, ...
Clinical Lymphoma Myeloma and Leukemia 23, S166, 2023
2023
P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB+ AZACITIDINE COMPARED TO …
H Döhner, P Montesinos, SV Polo, E Zarzycka, J Wang, M Riva, M Heuser, ...
HemaSphere 7 (S3), e83152da, 2023
2023
Oral Abstract: AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib+ Azacitidine Versus Placebo+ Azacitidine in Patients With Newly Diagnosed Acute …
H Dohner, P Montesinos, SV Polo, E Zarzycka, J Wang, G Bertani, ...
Clinical Lymphoma Myeloma and Leukemia 22, S115, 2022
2022
Poster: AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib+ Azacitidine Versus Placebo+ Azacitidine in Patients With Newly Diagnosed Acute Myeloid …
H Dohner, P Montesinos, SV Polo, E Zarzycka, J Wang, G Bertani, ...
Clinical Lymphoma, Myeloma and Leukemia 22, S124, 2022
2022
Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.
H Dohner, P Montesinos, SV Polo, E Zarzycka, J Wang, G Bertani, ...
JOURNAL OF CLINICAL ONCOLOGY 40 (16), 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–20